
Novita makes spunlace and needlepunched nonwovens for personal care and medical buyers, with custom colors, designs, and individual project approaches.
novita.plCrawled Nov 22, 2026
Novita S.A. releases its financial performance for the third quarter and first nine months of 2026, covering the period ending September 30. The report details earnings metrics and operational updates for the Polish biotechnology company specializing in regenerative medicine. Investors and stakeholders review the results to assess growth trends and strategic progress.
Novita S.A. reports a net income of **PLN 10.7 million** for the first half of 2026, up from **PLN 10.19 million** in the same period the prior year. Basic earnings per share from continuing operations rise to **PLN 4.28**, compared to **PLN 4.08** year-over-year. The results reflect continued financial growth for the Polish company.
Novita S.A. declares an annual dividend of **PLN 8.00 per share**, set for payment on **August 27, 2026**. The ex-date is **June 29, 2026**, and the record date is **June 30, 2026**. Shareholders meeting eligibility criteria will receive the payout.
Novita installs an Andritz spunlace production line to expand its nonwoven fabric capabilities. The facility targets high-growth hygiene and medical markets, leveraging the line’s efficiency for disposable products like surgical gowns and sanitary pads. The investment strengthens Novita’s position in specialized nonwoven applications.
Tebesa Sp. z o.o. has acquired a **63.17% stake in Novita S.A.** from Lentex S.A. for **PLN 82.8 million**. The transaction was finalized following a **letter of intent signed in April 2016**. Novita S.A. (WSE:NVT) and Lentex S.A. (WSE:LTX) are both listed on the Warsaw Stock Exchange.